资源描述：
《关于芬必得（布洛芬）临床研究进展 About Fenbid (ibuprofen) clinical research progress》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、药理学(论文)课题名称关于芬必得（布洛芬）临床研究进展学生姓名学号1040903004系、年级专业生物与化学工程系10级生物工程班指导教师6AboutFenbid(ibuprofen)clinicalresearchprogressAbstract:InordertounderstandthevarietyofclinicalperformanceFenbiddrugs,clinicaltreatmentofdifferentdiseasesintheapplicationFenbidmechanismofactionofthedrugs,anti-inflammatory,an
2、algesic,antipyreticdrugs.TheFenbiddrugsinthetreatmentofrheumatoidarthritis,rheumatoidarthritis,osteoarthritis,ankylosingspondylitis,neuritissymptomshaveagoodeffect.Keywords:ibuprofen;osteoarthritis;antipyreticanalgesic;interaction关于芬必得（布洛芬）临床研究进展摘要：为了了解芬必得药物的各种临床效能，通过不同的疾病临床治疗在应用芬必得药物的作用机制，可以
3、确定此药物有抗炎、镇痛、解热等作用。芬必得药物在治疗风湿性关节炎、类风湿性关节炎、骨关节炎、强直性脊椎炎和神经炎等症状都有很好的效果。关键词：布洛芬；骨关节炎；解热镇痛；相互作用1.Fenbidintroduction1.1ChemicalcompositionThemainingredientisibuprofen,thechemicalnameof2-(4-isobutylphenyl)propionicacid,molecularweightof206.28.1.2DomesticproductsFenbidIbuprofenSustainedReleaseCapsules
4、,Fenbidcreams,headachemountedFenbid,phenolcoffeepieceFenbid(Fenbidnewheadacheinstalled)1.3MechanismofactionIbuprofenbyinhibitinginducibleinducedinflammatorycyclooxygenase6metabolismofarachidonicmediaprostaglandinsorotherneurotransmittersynthesis,reducingtheprostaglandin-inducedlocaltissuecong
5、estion,swelling,fever[1];inhibitleukocyteactivityanddissolvedenzymereleasingreducethepartialsciaticnervepainsensitivity,reducethepaincausedbysubstancessuchasbradykininorganizationalimpulseanalgesiceffect[2].Ibuprofenforthetreatmentofdysmenorrheamechanismmaybetheinhibitionofprostaglandinpressu
6、redropwithintheuterus,contractionsreduce.Byanti-inflammatory,analgesicibuprofencanrelievegout[3].2.FenbiddrugmetabolismEasyabsorptionoforalibuprofen,slowabsorptionwithfoodandclothes,butdoesnotaffecttheuptake,plasmaproteinbindingrate(thepercentageofdrugintheplasmaintheplasmaproteinbinding)of99
7、%[4],1.2~2.1hoursaftertakingthebloodthepeakplasmaconcentration,synovialfluidconcentrationsequaltotheplasmaconcentrationafter5hours,within12hoursafterthesynovialfluidconcentrationshigherthanplasmaconcentrations.Thehalf-life(drugplasmaconcentra
